The last couple weeks on the market have been punishing for formerly highflying drug and device stocks. But one common side effect of lower valuations is more buyouts, which fanned a fair bit of Wall Street chatter and speculation this week. Here are the three getting the most attention. The most likely to be true: on Friday afternoon, Bloomberg reported that Baxalta (BXLT), the recently spun-off biopharma arm of Baxter International (BAX), is
Medical products giant Baxter International (BAX) beat Q3 earnings estimates and lifted its 2014 organic sales growth guidance Thursday, though it lowered its EPS outlook due to a divestiture. Its stock initially dropped but by early afternoon was up a fraction on the stock market today. Baxter’s sales rose 13% over the year-earlier quarter to $4.2 billion, in line with analysts’ consensus. Earnings climbed 9% to $1.35 a share, beating estimates
Medical-product maker Baxter International (BAX) beat analysts’ Q2 expectations Thursday, but its conservative guidance underwhelmed the Street. Shares dropped early but recovered and was flat in midday trading in the stock market today. Baxter’s Q2 earnings rose 5% over the year-earlier quarter to $1.26 a share, topping analysts’ consensus by 4 cents. Sales rose 16% to $4.3 billion, beating analysts’ $4.1 billion. Baxter narrowed its full-year